Spyre Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SYRE Nasdaq 2836 www.spyre.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spyre Therapeutics, Inc.

Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance - Jan 17th, 2026 4:08 am
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Jan 15th, 2026 9:35 am
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 - Jan 12th, 2026 6:00 am
Spyre Therapeutics' CEO Sells 15,000 Shares - Jan 11th, 2026 7:37 am
Spyre Therapeutics Announces Grants of Inducement Awards - Jan 8th, 2026 2:05 pm
Spyre Therapeutics (SYRE): Assessing Valuation After a Sharp Momentum-Driven Share Price Surge - Dec 10th, 2025 7:09 am
A Short Squeeze Could Send This Little-Known Biotech Stock Soaring - Dec 8th, 2025 9:30 am
Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls - Dec 1st, 2025 7:46 am
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 - Nov 17th, 2025 10:15 am
Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? - Nov 9th, 2025 3:07 pm
Spyre Therapeutics: Q3 Earnings Snapshot - Nov 4th, 2025 2:54 pm
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 4th, 2025 2:05 pm
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody - Nov 4th, 2025 2:01 pm
Spyre Therapeutics to Participate in Upcoming November Investor Conferences - Oct 29th, 2025 2:05 pm
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 - Oct 24th, 2025 6:00 am
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - Oct 15th, 2025 2:15 pm
Spyre Therapeutics (SYRE): Assessing Valuation Following Major Equity Offering and Share Price Surge - Oct 14th, 2025 8:10 pm
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - Oct 13th, 2025 7:07 pm
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants - Oct 13th, 2025 2:01 pm
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - Oct 5th, 2025 7:00 am